Drug
Glembatumumab vedotin clinical trials
Also written CDX-011 and CR011-vcMMAE.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 5
National Cancer Institute (NCI) (3) · Celldex Therapeutics (3) · CuraGen Corporation (2) · PrECOG, LLC. (1) · University of Virginia (1)
Often tested with
Tested in the same studies.
Varlilumab (1) · CDX-301 (1) · flt3 ligand protein (1) · Ipilimumab (1) · Nivolumab (1)
Studies
Open first, then newest update. How each study uses glembatumumab vedotin is read from its arms, and is right about nine times in ten.
Testing it · 10
- Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerWithdrawnEarly Phase 1University of VirginiaNCT03473691Written as Glembatumumab Vedotin
- Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedPhase 2National Cancer Institute (NCI)NCT02487979Written as Glembatumumab Vedotin
- Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT02363283Written as Glembatumumab Vedotin
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedPhase 2Celldex TherapeuticsNCT02302339Written as glembatumumab vedotin
- Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the LungTerminatedPhase 1/2PrECOG, LLC.NCT02713828Written as Phase I: Glembatumumab Vedotin
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast CancerCompletedPhase 2Celldex TherapeuticsNCT01997333Written as CDX-011
- Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnPhase 1/2National Cancer Institute (NCI)NCT03326258Written as Glembatumumab Vedotin
- A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast CancerCompletedPhase 2Celldex TherapeuticsNCT01156753Written as CDX-011
- Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast CancerCompletedPhase 1/2CuraGen CorporationNCT00704158Written as CR011-vcMMAE
- A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV MelanomaCompletedPhase 1/2CuraGen CorporationNCT00412828Written as CR011-vcMMAE
Codes
What other systems call glembatumumab vedotin · ClinicalTrials.gg INT005673
- MeSH (NLM) C551271glembatumumab vedotinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1568H6A58UGLEMBATUMUMAB VEDOTINConfirmed FDA, NLM, Wikidata
- Wikidata Q3771944glembatumumab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78449Glembatumumab VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551271 | glembatumumab vedotin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1568H6A58U | GLEMBATUMUMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3771944 | glembatumumab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78449 | Glembatumumab Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.